Quoin Pharmaceuticals (QNRX) announced recent corporate accomplishments and provided an update on its fourth quarter and full-year 2024 ...
Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) is anticipated to post its quarterly earnings results before the market ...
Fourth Quarter 2024 Highlights On Dec. 20, 2024, Quoin announced the successful completion of a $6.8 million public offering, bolstering the company’s financial position to support ongoing clinical ...
Hosted on MSN8d
QNRX: More Positive Data Supporting Efficacy of QRX003 for NS; Campaign to Raise Awareness of the DiseaseQNRX READ THE FULL QNRX RESEARCH REPORT Positive interim clinical data Quoin Pharmaceuticals (NASDAQ:QNRX) is a clinical stage, specialty pharmaceutical company that focuses on developing treatments ...
$QNRX insiders have traded $QNRX stock on the open market 17 times in the past 6 months. Of those trades, 17 have been purchases and 0 have been sales.
ASHBURN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty ...
Quoin Pharmaceuticals, Ltd. (QNRX) stock price is 0.31 and Quoin Pharmaceuticals, Ltd. (QNRX) 10-day simple moving average is 0.31. Quoin Pharmaceuticals, Ltd. (QNRX) stock price is 0.31 and Quoin ...
1 Day QNRX -0.19% DJIA -0.08% Russell 2K -0.09% Health Care/Life Sciences -0.32% ...
Short interest in Quoin Pharmaceuticals Ltd (NASDAQ:QNRX) decreased during the last reporting period, falling from 410.40K to 52.82K. This put 0.66% of the company's publicly available shares short.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback